Bisphosphonate use in children with cerebral palsy
Referencias
Additional references
Allington N, Vivegnis D, Gerard P. Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. Acta Orthopædica Belgica 2005;71(1):91‐7. [PUBMED: 15792214]
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Chapter 24: Multiple outcomes or time‐points within a study. Introduction to Meta‐Analysis. Chichester: John Wiley & Sons, Ltd, 2009.
Boyce AM, Tosi LL, Paul SM. Bisphosphonate treatment for children with disabling conditions. PM & R: the Journal of Injury, Function, and Rehabilitation 2014;6(5):427–36. [DOI: 10.1016/j.pmrj.2013.10.009; PMC4037384; PUBMED: 24368091]
Campbell M, Grimshaw J, Steen N, The Changing Professional Practice in Europe Group (EU BIOMED II Concerted Action). Sample size calculations for cluster randomised trials. Journal of Health Services Research & Policy 2000;5(1):12‐6. [DOI: 10.1177/135581960000500105; PUBMED: 10787581]
Cohran V, Cassedy A, Hawkins A, Bean J, Heubi J. Oral risedronate sodium improves bone mineral density in non‐ambulatory patients: a randomized, double‐blind, placebo controlled trial. Journal of Pediatric Rehabilitation Medicine 2013;6(2):85‐93. [DOI: 10.3233/PRM‐130242; PUBMED: 23803341]
Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD005088.pub3]
Egger M, Davey Smith G. Meta‐analysis: potentials and promise. BMJ 1997;315(7119):1371–4. [PMC2127866; PUBMED: 9432250]
Fehlings D, Switzer L, Agarwal P, Wong C, Sorchett E, Stevenson R, et al. Informing evidence‐based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: a systematic review. Developmental Medicine and Child Neurology 2012;54(2):106‐16. [DOI: 10.1111/j.1469‐8749.2011.04091.x; PUBMED: 22111966]
McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 23 May 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6. [DOI: doi.org/10.1136/bmj.39489.470347.AD; PMC2335261; PUBMED: 18436948]
Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso‐Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence — imprecision. Journal of Clinical Epidemiology 2011;64(12):1283–93. [DOI: 10.1016/j.jclinepi.2011.01.012; PUBMED: 21839614]
Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo‐controlled clinical trial. The Journal of Paediatrics 2002;141(5):644‐51. [DOI: 10.1067/mpd.2002.128207; PUBMED: 12410192]
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hough JP, Boyd RN, Keating JL. Systematic review of interventions for low bone mineral density in children with cerebral palsy. Paediatrics 2010;125(3):670‐8. [DOI: 10.1542/peds.2009‐0292; PUBMED: 20123765]
Iwasaki T, Takei K, Nakamura S, Hosoda N, Yokota Y, Ishii M. Secondary osteoporosis in long‐term bedridden patients with cerebral palsy. Pediatrics International 2008;50(3):269‐75. [DOI: 10.1111/j.1442‐200X.2008.02571.x; PUBMED: 18533934]
Iwasaki T, Nonoda Y, Ishii M. Long‐term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis. Current Medical Research and Opinion 2012;28(8):737‐47. [DOI: 10.1185/03007995.2011.645562; PUBMED: 22126423]
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate‐associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 2007;22(10):1479‐91. [10.1359/jbmr.0707onj; 17663640]
Mergler S, Evenhuis HM, Boot AM, De Man SA, Bindels‐De Heus KG, Huijbers WA, et al. Epidemiology of low bone mineral density and fractures in children with severe cerebral palsy: a systematic review. Developmental Medicine and Child Neurology 2009;51(10):773–8. [DOI: 10.1111/j.1469‐8749.2009.03384.x; PUBMED: 19614941]
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097; PMC2707599; PUBMED: 19621072]
National Institutes of Health Consensus Development Panel on Osteoporosis Prevention, Diagnosis, Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785‐95. [DOI: 10.1001/jama.285.6.785; PUBMED: 11176917]
Palisano RJ, Hanna SE, Rosenbaum PL, Russell DJ, Walter SD, Wood EP, et al. Validation of a model of gross motor function for children with cerebral palsy. Physical Therapy 2000;80(10):974‐85. [PUBMED: 11002433]
Pharoah PO, Cooke T, Johnson MA, King R, Mutch L. Epidemiology of cerebral palsy in England and Scotland, 1984–9. Archives of Disease in Childhood. Fetal and Neonatal Edition 1998;79(1):F21‐5. [PMC1720819; PUBMED: 9797620]
Rao JNK, Scott AJ. A simple method for the analysis of clustered binary data. Biometrics 1992;48(2):577‐85. [PUBMED: 1637980]
Reddihough DS, Collins KJ. The epidemiology and causes of cerebral palsy. The Australian Journal of Physiotherapy 2003;49(1):7‐12. [PUBMED: 12600249]
Reid SM, Carlin JB, Reddihough DS. Using the Gross Motor Function Classification System to describe patterns of motor severity in cerebral palsy. Developmental Medicine and Child Neurology 2011;53(11):1007‐12. [DOI: 10.1111/j.1469‐8749.2011.04044.x; PUBMED: 22014320]
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Russell RG. Bisphosphonates: the first 40 years. Bone 2011;49(1):2‐19. [DOI: 10.1016/j.bone.2011.04.022; PUBMED: 21555003]
Johnson A. Prevalence and characteristics of children with cerebral palsy in Europe. Developmental Medicine and Child Neurology 2002;44(9):633–40. [PUBMED: 12227618]
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 2014;29(1):1‐23. [DOI: 10.1002/jbmr.1998; PUBMED: 23712442]
Stanley F. Cerebral palsy and newborn care: I, II, and III (1981). Developmental Medicine and Child Neurology 2008;50(12):886. [DOI: 10.1111/j.1469‐8749.2008.03180.x; PUBMED: 19046182]
Stevenson RD, Conaway M, Barrington JW, Cuthill SL, Worley G, Henderson RC. Fracture rate in children with cerebral palsy. Paediatric Rehabilitation 2006;9(4):396‐403. [PUBMED: 17111566]
Sullivan PB. Gastrointestinal disorders in children with neurodevelopmental disabilities. Developmental Disabilities Research Reviews 2008;14(2):128‐36. [DOI: 10.1002/ddrr.18; PUBMED: 18646021]
Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1‐34) for 2 years and relevance to human safety. Toxicologic Pathology 2002;30(3):312‐21. [DOI: 10.1080/01926230252929882; PUBMED: 12051548]
Ward L, Tricco A, Phuong PN, Cranney A, Barrowman N, Gaboury I, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005324.pub2]
Zemel BS, Kalkwarf HJ, Gilsanz V, Lappe JM, Oberfield S, Shepherd JA, et al. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non‐black children: results of the bone mineral density in childhood study. The Journal of Clinical Endocrinology and Metabolism 2011;96(10):3160‐9. [DOI: 10.1210/jc.2011‐1111; PMC3200252; PUBMED: 21917867]
